Sanofi (ETR:SNW)
Germany · Delayed Price · Currency is EUR 83.37
-1.40 (-1.65%)
Oct 10, 2025, 5:35 PM CET
Sanofi Revenue
Sanofi had revenue of 10.74B EUR in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to 45.74B, up 15.65% year-over-year. In the year 2024, Sanofi had annual revenue of 44.29B with 7.73% growth.
Revenue (ttm)
45.74B
Revenue Growth
+15.65%
P/S Ratio
2.22
Revenue / Employee
551.87K
Employees
82,878
Market Cap
101.41B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 44.29B | 3.18B | 7.73% |
| Dec 31, 2023 | 41.11B | 805.00M | 2.00% |
| Dec 31, 2022 | 40.30B | 1.13B | 2.88% |
| Dec 31, 2021 | 39.18B | 1.81B | 4.83% |
| Dec 31, 2020 | 37.37B | -262.00M | -0.70% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Siemens Healthineers AG | 23.38B |
| Merck KGaA | 21.22B |
| Bayer Aktiengesellschaft | 46.17B |
| Fresenius SE & Co. KGaA | 22.28B |
| Sartorius Aktiengesellschaft | 3.47B |
| Fresenius Medical Care AG | 19.52B |
| Fielmann Group AG | 2.40B |
| Carl Zeiss Meditec AG | 2.18B |
Sanofi News
- 2 days ago - Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out - Investor's Business Daily
- 3 days ago - Sanofi and Orano Med succeed in mid-stage trial for neuroendocrine tumor therapy - Seeking Alpha
- 3 days ago - BenchSci Announces Three-Year License Agreement with Sanofi to Access and Use BenchSci's ASCEND Platform - Business Wire
- 3 days ago - Sanofi's AlphaMedix Shows Strong Phase 2 Results For Advanced Neuroendocrine Tumor Treatment - Nasdaq
- 3 days ago - Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors - GlobeNewsWire
- 4 days ago - Novavax (NVAX) Transfers EU Vaccine Rights to Sanofi for $25M - GuruFocus
- 4 days ago - Novavax hands over Nuvaxovid marketing rights to Sanofi in the EU - Seeking Alpha
- 4 days ago - Sanofi (SNY) Gains Full EU Control of Nuvaxovid from Novavax - GuruFocus